|1.||Gambhir, Sanjiv S: 7 articles (05/2012 - 03/2002)|
|2.||Wu, Lily: 7 articles (10/2011 - 03/2002)|
|3.||Carey, Michael: 6 articles (01/2006 - 03/2002)|
|4.||Gambhir, S S: 4 articles (06/2011 - 12/2001)|
|5.||Iyer, Meera: 4 articles (01/2006 - 03/2002)|
|6.||Zhang, Liqun: 4 articles (05/2005 - 03/2002)|
|7.||Sato, Makoto: 3 articles (10/2011 - 11/2003)|
|8.||Wu, L: 3 articles (04/2008 - 12/2001)|
|9.||Carey, M: 3 articles (04/2008 - 12/2001)|
|10.||Shen, Keng: 2 articles (07/2014 - 09/2007)|
05/01/2012 - "With intratumoral delivery, Ad-pSurvivin-TSTA-TRAIL-FL showed positive FL signal from all tumors and better therapeutic efficacy than Ad-pCMV-FL on day 7 (2.4 ± 0.50 vs 5.4 ± 0.78; P = .01). "
05/01/2012 - "With intravenous delivery, Ad-pSurvivin-TSTA-TRAIL-FL showed no measurable liver tumor FL signal on day 1 after delivery, but showed better therapeutic efficacy than Ad-pCMV-FL on day 7 (PET tumor/liver ratio, 3.5 ± 0.58 vs 6.0 ± 0.71; P = .02). "
01/15/1990 - "VVpyMT-Cfr and VVpyMT were equally effective in eliciting tumor immunity, indicating the presence of a major TSTA epitope within the unique C-terminal region of MT."
09/01/1984 - "Moreover, the strongly immunogenic LTC-1 hybrid cells, but not the parent tumor cells, were effective in priming recipient spleen cells to generate TEPC-15 tumor-specific cytotoxic cells upon subsequent in vitro exposure to the TSTA-bearing cells. "
01/01/2006 - "The results from this study support the use of TSTA-based lentiviral vectors for prostate tumor targeting after systemic delivery. "
|2.||Neoplasm Metastasis (Metastasis)
10/01/2011 - "Moreover, intravenous administrated PSES-TSTA bioluminescent vector correctly identified tibial bone marrow metastases in 9 of 9 animals, whereas NaF- and FDG-PET was unable to detect the lesions. "
12/20/1984 - "[The immunotherapeutic effect of partially purified tumor specific transplantation antigen against pulmonary metastasis]."
11/01/1989 - "Thus TSTA/CY/CTL therapy activates tumoricidal host responses effective against the poorly immunogenic MCA-SP tumor and its lymph-node metastases."
10/01/1980 - "acnes) on metastasis formation of C3H/He mice which has been rendered tolerant to tumor-associated transplantation antigen (TATA) of syngeneic X5563 plasmacytoma. "
01/01/1988 - "In a spontaneous pulmonary metastasis model following amputation of a tumor-bearing limb, the triple regimen of TSTA/CY/RTT-2 markedly reduced the number of lung colonies. "
|3.||Prostatic Neoplasms (Prostate Cancer)
05/15/2005 - "A highly augmented, prostate-specific two-step transcriptional amplification (TSTA) method was developed with the ultimate goal of delivering an effective and safe gene-based treatment to prostate cancer patients. "
08/01/2006 - "A two-step transcriptional amplification system (TSTA) was used to enhance the efficacy of suicide gene therapy for treatment of prostate cancer. "
03/01/2007 - "These results highlight that the recombinant PPT sequence is active in murine prostate cancer cells when augmented by a TSTA system. "
03/01/2007 - "Herein, we describe that the PPT sequence in combination with a two-step transcriptional amplification (TSTA) system becomes active also in murine prostate cancer cells. "
05/15/2005 - "Together with the fact that majority of recurrent prostate cancers express AR and PSA, we foresee that the TSTA approach can be a promising gene therapy strategy for the advanced stages of prostate cancer."
|4.||Sarcoma (Soft Tissue Sarcoma)
11/01/1980 - "The therapeutic effect of TSTA was immunologically specific: Animals cured of local MCA-F recurrences promptly died from primary challenge with the non-cross-reacting sarcoma MCA-D. "
01/01/1989 - "Cross-reacting tumor associated transplantation antigen on primary 3-methylcholanthrene-induced BALB/c sarcomas."
10/15/1984 - "Isolation of a tumor-associated transplantation antigen (TATA) from an SV40-induced sarcoma. "
04/01/1984 - "These procedures provide a means for successful separation of immunogenic SV40- and Adv-7-induced TSTA from detectable, biologically active, cross-protective EA from the surfaces of these sarcoma cells."
01/01/1982 - "Rabbits immunized with the immunoprotective TSTA fraction partially purified by preparative isoelectric focusing of 3 M KCl extracts from a chemically induced murine sarcoma, MCA-F, produced specific xenoantisera as assessed by an indirect membrane immunofluorescence assay. "
04/15/1983 - "In this study we have analyzed the in vitro cell-mediated cytotoxicity of immune peritoneal exudate cells (PEC), elicited in syngeneic mice against the MCA-induced, TSTA-bearing BALB/c fibrosarcoma CA-2, GI-17 and C-3. "
05/01/1983 - "We have analyzed the complexity of a unique tumor-specific transplantation antigen expressed by the murine ultraviolet light-induced fibrosarcoma 1591-RE. "
08/15/1987 - "The weakly immunogenic murine fibrosarcoma MCA-F was used because we have previously characterized the tumor-specific transplantation antigen expressed by this tumor. "
07/15/1987 - "Two polyoma-TSTA-negative variants were selected independently from a polyoma fibrosarcoma/Moloney lymphoma somatic hybrid, by repeated passages in polyoma-virus-preimmunized mice. "
10/15/1980 - "Expression of alien minor histocompatibility antigens distinct from tumor-specific transplantation antigen on a murine fibrosarcoma."
|2.||Telomerase (Telomerase Reverse Transcriptase)
|3.||Histocompatibility Antigens (Histocompatibility Antigen)
|6.||telomerase RNA (bTR)
|8.||tumor-associated transplantation antigen (TSTA)
|9.||Caspase 3 (Caspase-3)
|10.||Histocompatibility Antigens Class I
|1.||Transplantation (Transplant Recipients)
|3.||Heterologous Transplantation (Xenotransplantation)